Induction of antigen-specific TH9 immunity accompanied by mast cell activation blocks tumor cell engraftment

International Journal of Cancer

Volumn 139, Issue 4, 2016, Pages 841-853

  Abdul Wahid, Aws ^a,b   Cydzik, Marzena ^b   Prodeus, Aaron ^a,b   Alwash, Mays ^b,c   Stanojcic, Mile ^c   Thompson, Megan ^b   Huang, Eric H B ^b   Shively, John E ^d   Gray Owen, Scott D ^a   Gariépy, Jean ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Canada   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

cancer vaccine; metastatic dissemination; TH9 immunity; toll like receptor 3; tumor cell engraftment

Indexed keywords

DOUBLE STRANDED RNA; INTERLEUKIN 9; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT ANTIGEN; RECOMBINANT CARCINOEMBRYONIC ANTIGEN IMMUNOGLOBULIN V LIKE N DOMAIN; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER INHIBITION; CELL ACTIVATION; CELLULAR IMMUNITY; CIRCULATING TUMOR CELL; COLON CARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG TARGETING; IMMUNE RESPONSE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN RNA BINDING; SIGNAL TRANSDUCTION; TH9 CELL; TUMOR ENGRAFTMENT; VACCINATION;

EID: 84976537518     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30121     Document Type: Article

References (44)

1. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009;9:285–93.
2. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009;9:302–12.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
4. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 2002;20:2197–207.
5. Abdul-Wahid A, Huang EH, Lu H, et al. A focused immune response targeting the homotypic binding domain of the carcinoembryonic antigen blocks the establishment of tumor foci in vivo. Int J Cancer 2012;131:2839–51.
6. Abdul-Wahid A, Huang EH, Cydzik M, et al. The carcinoembryonic antigen IgV-like N domain plays a critical role in the implantation of metastatic tumor cells. Mol Oncol 2014;8:337–50.
7. Finn OJ. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol Res 2014;2:708–13.
8. Curigliano G, Spitaleri G, Pietri E, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 2006;17:750–62.
9. Matsuda K, Tsunoda T, Tanaka H, et al. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 2004;53:609–16.
10. Bos R, van Duikeren S, Morreau H, et al. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008;68:8446–55.
11. Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14:3060–9.
12. Dai S, Wei D, Wu Z, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 2008;16:782–90.
13. Crosti M, Longhi R, Consogno G, et al. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol 2006;176:5093–9.
14. Orava EW, Abdul-Wahid A, Huang EH, et al. Blocking the attachment of cancer cells in vivo with DNA aptamers displaying anti-adhesive properties against the carcinoembryonic antigen. Mol Oncol 2013;7:799–811.
15. Abdul-Wahid A, Faubert G. Mucosal delivery of a transmission-blocking DNA vaccine encoding Giardia lamblia CWP2 by Salmonella typhimurium bactofection vehicle. Vaccine 2007;25:8372–83.
16. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 2010;10:683–7.
17. Gorczynski RM, Chen Z, Khatri I, et al. Graft-infiltrating cells expressing a CD200 transgene prolong allogeneic skin graft survival in association with local increases in Foxp3(+)Treg and mast cells. Transpl Immunol 2011;25:187–93.
18. Gorczynski R, Yu K, Chen Z. Anti-CD200R2, anti-IL-9, anti-IL-35, or anti-TGF-β abolishes increased graft survival and Treg induction induced in cromolyn-treated CD200R1KO.CD200tg mice. Transplantation 2014;97:39–46.
19. Khan WI, Richard M, Akiho H, et al. Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: correlation with worm expulsion in murine nematode infections. Infect Immun 2003;71:2430–8.
20. Licona-Limón P, Henao-Mejia J, Temann AU, et al. Th9 cells drive host immunity against gastrointestinal worm infection. Immunity 2013;39:744–57.
21. Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001;15:985–95.
22. Faulkner H, Humphreys N, Renauld JC, et al. Interleukin-9 is involved in host protective immunity to intestinal nematode infection. Eur J Immunol 1997;27:2536–40.
23. Leech MD, Grencis RK. Induction of enhanced immunity to intestinal nematodes using IL-9-producing dendritic cells. J Immunol 2006;176:2505–11.
24. Goswami R, Kaplan MH. A brief history of IL-9. J Immunol 2011;186:3283–8.
25. Cheng G, Arima M, Honda K, et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 2002;166:409–16.
26. Kung TT, Luo B, Crawley Y, et al. Effect of anti-mIL-9 antibody on the development of pulmonary inflammation and airway hyperresponsiveness in allergic mice. Am J Respir Cell Mol Biol 2001;25:600–5.
27. Chang HC, Sehra S, Goswami R, et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol 2010;11:527–34.
28. Staudt V, Bothur E, Klein M, et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 2010;33:192–202.
29. Hoelzinger DB, Dominguez AL, Cohen PA, et al. Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges. Cancer Res 2014;74:6845–55.
30. Lu Y, Hong S, Li H, et al. Th9 cells promote antitumor immune responses in vivo. J Clin Invest 2012;122:4160–71.
31. Purwar R, Schlapbach C, Xiao S, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012;18:1248–53.
32. Nakatsukasa H, Zhang D, Maruyama T, et al. The DNA-binding inhibitor Id3 regulates IL-9 production in CD4+ T cells. Nat Immunol 2015;16:1077–84.
33. Kim IK, Kim BS, Koh CH, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat Med 2015;21:1010–7.
34. Seubert A, Monaci E, Pizza M, et al. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 2008;180:5402–12.
35. Szabo A, Rajnavolgyi E. Collaboration of Toll-like and RIG-I-like receptors in human dendritic cells: tRIGgering antiviral innate immune responses. Am J Clin Exp Immunol 2013;2:195–207.
36. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34:637–50.
37. Cheng K, Wang X, Yin H. Small-molecule inhibitors of the TLR3/dsRNA complex. J Am Chem Soc 2011;133:3764–7.
38. Oldford SA, Marshall JS. Mast cells as targets for immunotherapy of solid tumors. Mol Immunol 2015;63:113–24.
39. Xia Q, Wu XJ, Zhou Q, et al. No relationship between the distribution of mast cells and the survival of stage IIIB colon cancer patients. J Transl Med 2011;9:88.
40. Hedström G, Berglund M, Molin D, et al. Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 2007;138:68–71.
41. Chan JK, Magistris A, Loizzi V, et al. Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. Gynecol Oncol 2005;99:20–5.
42. Wang B, Li L, Liao Y, et al. Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. Cancer Immunol. Immunother 2013;62:1575–85.
43. Nowak EC, Weaver CT, Turner H, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009;206:1653–60.
44. Li QY, Raza-Ahmad A, MacAulay MA, et al. The relationship of mast cells and their secreted products to the volume of fibrosis in posttransplant hearts. Transplantation 1992;53:1047–51.